<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Snapshot &#187; Fragmin</title>
	<atom:link href="http://www.raymondstevenson.com/tag/fragmin/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.raymondstevenson.com</link>
	<description>Expert and creative communications services for the pharmaceutical and biotechnology industries.</description>
	<lastBuildDate>Mon, 06 Feb 2012 12:51:55 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>Product Expertise</title>
		<link>http://www.raymondstevenson.com/case-studies/product-expertise/</link>
		<comments>http://www.raymondstevenson.com/case-studies/product-expertise/#comments</comments>
		<pubDate>Thu, 01 Oct 2009 17:38:19 +0000</pubDate>
		<dc:creator>theadmin</dc:creator>
				<category><![CDATA[Case Studies]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Fragmin]]></category>

		<guid isPermaLink="false">http://www.raymondstevenson.com/?p=893</guid>
		<description><![CDATA[FDA Cardiology Advisory Committee to review Fragmin for QOL indication for terminal cancer patients]]></description>
			<content:encoded><![CDATA[<table id="cs_head" class="blue_bg" border="0" width="100%">
<tbody>
<tr>
<td align="left"><img class="alignleft size-full wp-image-895" src="http://www.raymondstevenson.com/wp-content/uploads/2009/10/Fragmin.jpg" alt="Fragmin" width="247" height="116" /></td>
<td width="100%"><img class="aligncenter size-full wp-image-511" src="http://www.raymondstevenson.com/wp-content/uploads/2009/09/fda.jpg" alt="fda" width="144" height="100" /></td>
</tr>
</tbody>
</table>
<h4><strong>Context</strong>:</h4>
<ul>
<li> FDA Cardiology Advisory Committee to review blood-thinner Fragmin for quality of life indication in terminal cancer patients</li>
</ul>
<h4><strong>Challenge:</strong></h4>
<ul>
<li>Higher mortality rates in Fragmin study arm viewed negatively by FDA</li>
</ul>
<h4><strong>Solution</strong>:</h4>
<ul>
<li>Advised Pfizer team how to clarify the misunderstanding and revised the proposal flow</li>
</ul>
<h4><strong>Results</strong>:</h4>
<ul>
<li> Unanimous approvable recommendation by the FDA Committee for the new indication</li>
</ul>
]]></content:encoded>
			<wfw:commentRss>http://www.raymondstevenson.com/case-studies/product-expertise/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

